Lionheart Health to Showcase Regenerative Technology at Octane Medical Innovation Forum

Lionheart Health, Inc., operator of Lionheart Longevity & Wellness Clinics, will present at the 2025 Octane Medical Innovation Forum focused on The Science of Longevity, scheduled for October 28-29, 2025, in Irvine, California. The forum brings together industry experts, entrepreneurs, investors, and thought leaders for two days of learning, networking, and innovation on the latest medical industry trends. Howard Leonhardt, Executive Chairman and co-Chief Executive Officer of Lionheart Health, will present the company's latest developments in regenerative aesthetics and healthspan longevity technologies.

The company's first-in-class technology platform utilizes precise patented bioelectric signaling sequences to trigger the release of regeneration-promoting proteins on demand. This includes controlled expression of klotho, a protein identified as crucial for aging management. One patented signaling sequence controls stem cell recruitment, proliferation, and differentiation as needed. The technology represents a significant advancement in the field of regenerative medicine, potentially offering new approaches to age-related health challenges.

Lionheart Health's business model involves licensing and supporting clinics worldwide with its patented technology platform in exclusive territories. Currently operating one clinic in Newport Beach, California, and seven other licensed locations, the company aims to establish 124 licensed sites within the next 60 months. This expansion strategy could significantly increase accessibility to their regenerative technologies across global markets. The company maintains an online presence at http://www.lionhearthealthstim.com where additional information about their services is available.

The company's recent achievements include being named a top 40 semi-finalist in the XPRIZE Healthspan Competition among 600 entries, focusing on improvements in muscle health, brain health, and immunity health with the goal of increasing healthy living years by two decades. They are currently working to advance to the top 10 finalist stage. Additional recognition includes winning Medtech Outlook Magazine's Top Micro Stimulator Implant Development of 2025 award, being a finalist in the Orange County Business Journal's Innovator of the Year Award, and current finalist status in the Octane High Tech Awards' Medical Innovation category. In December 2023, the company received the Abbvie Allergan ULP Golden Passport Award for innovation in medical aesthetics.

Lionheart Health's most ambitious project under development is a whole body regeneration chamber, described as a womb for adults. The company is currently building and testing prototypes, with plans to release an initial version using non-invasive technologies followed by an advanced version incorporating robotics, artificial intelligence, and implantable pump and stimulation technologies for internal organ regeneration. This project represents a potential paradigm shift in regenerative medicine approaches. The company's partnership with CoreViva for AI-enhanced MRI diagnostics and their long-standing relationship with University Lab Partners and the UCI Beall Applied Innovation Center Prototyping Lab further demonstrates their commitment to technological advancement. Event details can be found at https://www.octane-oc.org/event/omif/agenda for those interested in the forum proceedings.

The implications of Lionheart Health's technology platform extend beyond medical aesthetics to address fundamental aspects of human aging. As populations worldwide continue to age, solutions that can extend healthspan and improve quality of life during later years become increasingly valuable. The company's approach to organ regeneration and longevity science could potentially transform how healthcare addresses age-related conditions, reducing healthcare burdens and enabling longer, more productive lives. Their participation in the Octane Medical Innovation Forum provides an important platform for sharing these advancements with the broader medical community and potential partners.